Vesicor Therapeutics, Inc.

424B4 priced

Price $10.00

EFFECT effective

S-4/A amended

S-4/A amended

S-4/A amended

S-4/A amended

S-4/A amended

The current S-4/A filing details Black Hawk Acquisition Corporation's plan to merge with Vesicor Therapeutics, Inc., involving a domestication from the Cayman Islands to Delaware and a business combination. Key updates include late extension payments for the business combination deadline, a breach of governance terms, and ongoing efforts to complete the merger despite legal uncertainties. The filing also outlines capital structure changes, convertible note terms, and the continuation of shareholder approvals.

S-4/A amended

Vesicor Therapeutics, Inc. is undergoing a business combination with Black Hawk Acquisition Corporation, involving a domestication from the Cayman Islands to Delaware and a merger. The filing details extensions to the business combination deadline, late payments for these extensions, and the subsequent resolution. The company addresses risks related to delayed payments, potential liquidation, and legal claims, while proceeding with the merger and shareholder approvals.

S-4/A amended

Vesicor Therapeutics, Inc. is undergoing a business combination with Black Hawk Acquisition Corporation (SPAC), involving a merger and domestication from the Cayman Islands to Delaware. The transaction includes a share conversion, issuance of PubCo Common Stock, and assumption of warrants. The filing outlines the extension of the business combination timeline, funding through convertible notes, and the rebranding to Vesicor Therapeutics Holdings, Inc. following the merger.

S-4/A amended

The current S-4/A filing details Black Hawk Acquisition Corporation's plan to merge with Vesicor Therapeutics, Inc., involving a domestication from the Cayman Islands to Delaware and a subsequent merger. The transaction includes share conversions, trust account adjustments, and extension payments to delay the business combination deadline. The filing also outlines compensation for the Sponsor and risks related to the merger's completion and shareholder returns.

S-4 filed

Vesicor Therapeutics, Inc. is undergoing a business combination with Black Hawk Acquisition Corporation (SPAC), involving a merger and domestication from the Cayman Islands to Delaware. The transaction includes a name change to Vesicor Therapeutics Holdings, Inc., securities conversion, and redemption of public shares. The SPAC plans to extend the business combination timeline via convertible notes funded by the Sponsor, with $750,000 already deposited into the Trust Account.

DRS/A amended

Vesicor Therapeutics, Inc. filed a DRS/A on 2025-09-23 detailing financial updates, regulatory developments, and operational changes. The filing highlights increased operating expenses, $485,000 in gross proceeds from a 2025 Private Placement, and $320,000 in business combination-related payments. Financial comparisons show a net loss of $141,176 for Q1 2025 vs. $66,089 in Q1 2024, driven by higher general and administrative costs. The company anticipates rising expenses due to FDA approval processes and public company requirements. Liquidity concerns persist, with reliance on future capital raises.

DRS/A amended

Vesicor Therapeutics, Inc. is developing its ecm-RV/p53 product candidate, a novel therapeutic based on microvesicle technology, which has not yet received regulatory approval for clinical trials or commercial use. The company faces significant risks related to obtaining FDA approvals, competitive pressures, intellectual property protection, clinical trial success, and commercialization challenges. Key uncertainties include the novelty of its technology, reliance on regulatory discretion, and the potential for delays or failures in development and approval processes.